Selpercatinib is approved by FDA for locally advanced or metastatic RET fusion-positive solid tumors

Share This Post

November 2022: Selpercatinib (Retevmo, Eli Lilly and Company) received accelerated approval from the Food and Drug Administration to treat adult patients with RET-fused solid tumours that are locally or metastatically advanced, have progressed on or after prior systemic therapy, or who have no other effective treatment options.

In LIBRETTO-001 (NCT03157128), a multicenter, open-label, multi-cohort trial evaluating 41 patients with RET fusion-positive tumours (other than non-small cell lung cancer and thyroid cancer) who had disease progression during or after prior systemic treatment or who lacked adequate alternative treatment options, efficacy was shown. Data from 343 patients with RET fusion-positive NSCLC and thyroid cancer who were included in the same trial and previously mentioned in the product labelling provided support for the efficacy evaluation. Patients were given selpercatinib until the disease progressed or the side effects became intolerable.

A Blinded Independent Review Committee chose the overall response rate (ORR) and duration of response (DOR) as the major efficacy measures (BIRC). The ORR among the 41 individuals who could be evaluated was 44% (95% CI: 28, 60), and the DOR was 24.5 months (95% CI: 9.2, not estimable). Pancreatic adenocarcinoma, colorectal, salivary, unknown primary, breast, soft tissue sarcoma, bronchial carcinoid, ovarian, small intestine, and cholangiocarcinoma were among the tumour types that responded.

The patients’ average age was 50. (range 21 to 85). 54% of the population was female, 68% were White, 24% were Asian, 4.9% were Black, 7% were Hispanic/Latino, 95% had an ECOG performance rating of 0 or 1, and 95% had metastatic disease. 37 patients (90%) had previously had systemic therapy (median 2; range 0–9; 32% had previously received 3 or more). Pancreatic (27%), colorectal (24%), salivary (10%), and unknown primary (7%) malignancies were the most prevalent. Using NGS, 97.6% of patients had RET fusion-positive status found, while 2.4% did so using FISH.

Edema, diarrhoea, exhaustion, dry mouth, hypertension, abdominal discomfort, constipation, rash, nausea, and headache were the most frequent side events among patients (25%).

Based on body weight, the suggested dose of selpercatinib is:

120 milligrammes twice daily if you weigh less than 50 kg.
more than 50 kg: 160 mg taken orally twice each day.

 

View full prescribing information for Retevmo.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Risk of developing secondary tumors following CAR-T cell therapy is minimal - A Stanford Study
CAR T-Cell therapy

Risk of developing secondary tumors following CAR-T cell therapy is minimal – A Stanford Study

CAR-T cell therapy, a groundbreaking cancer treatment, carries a risk of developing secondary tumors. This occurs due to the therapy’s potential to cause genetic mutations or alter the immune system’s regulation. Secondary malignancies can arise from these changes, presenting a significant long-term risk for patients. Continuous monitoring and research are crucial to understanding and mitigating these risks, ensuring safer outcomes for those undergoing CAR-T cell therapy.

Seattle Children's Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients
CAR T-Cell therapy

Seattle Children’s Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients

Seattle Children’s Hospital is launching a groundbreaking CAR T-cell clinical trial for pediatric lupus patients. This innovative approach harnesses the body’s immune cells to target and eliminate lupus-affected cells, offering new hope for young patients with this autoimmune disorder. The trial represents a significant advancement in lupus treatment, aiming to improve outcomes and reduce long-term complications for children suffering from this challenging condition.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy